Magnus CRO provides specialized oncology biometrics services designed to address the complex requirements of cancer research. Our team supports trials across solid tumors, hematologic malignancies, and immuno-oncology therapies.
Oncology Biometrics Expertise
Our oncology statisticians and data managers deliver end-to-end support across all phases of oncology development—from early-stage dose escalation studies to global Phase III programs and post-marketing commitments.
- Study design, randomization, and adaptive trial simulations
- RECIST and irRECIST-based endpoint management
- Progression-free and overall survival analyses
- Central and local lab data reconciliation
- DMC charters, IDMC outputs, and interim reviews
Data Integrity and Compliance
All oncology deliverables are built to align with ICH-GCP, CDISC SDTM/ADaM standards, and 21 CFR Part 11 compliance, ensuring high-quality, submission-ready datasets and statistical outputs.